Aerie Pharmaecuticals is a clinical-stage biotechnology company that is dedicated to the discovery and development of novel treatments for glaucoma.  The company has identified two highly selective Rho-kinase (ROCK) inhibitors to lower intraocular pressure by improving outflow of fluid via the trabecular pathway with the potential of restoring normal function.

Avid Radiopharmaceuticals is developing new molecular imaging agents capable of changing the medical management of significant chronic human diseases; allowing early treatment and management of people at risk - before symptoms of disease can develop.  Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease, and Diabetes Mellitus. 

Acquired by Eli Lilly in December 2010

Cleave Biosciences is developing novel therapeutics targeting the Ubiquitin-Proteosome System (UPS), a cancer cell survival mechanism.

Clinipace Worldwide, a global digital clinical research organization that has pioneered technology-amplified contract research services, specializes in fully-integrated clinical research services for biopharmaceutical and medical device firms. Optimized by TEMPO™, its proprietary eClinical platform, the Clinipace team of experts brings extensive knowledge and insight into site selection, patient recruitment, clinical operations, data management, medical monitoring, biostatistics, and regulatory affairs to ensure a successful clinical development program through proactive clinical trial management.

Liquid Light is developing novel chemistry for the conversion of carbon dioxide to industrial-grade chemicals and fuels with disruptive economics over traditional petroleum-based manufacturing methods. Using electrochemisty, Liquid Light uses a novel combination of cathode material  and proprietary catalysts for efficient chemical conversion. 

Luxtera, Inc. is a fabless Silicon Photonics company with a unique technology platform to manufacture a new breed of monolithic opto-electronic devices in a low cost CMOS process. Luxtera’s CMOS Photonics™ devices are fully integrated with CMOS electronics and are orders of magnitude smaller (and often faster) than traditional photonic elements. The company’s vision is to deliver economic optical connectivity everywhere, from network level to intra-system level, and eventually chip-to-chip.

MC10, Inc. is developing electronic circuits that can stretch up to 400% with wide-ranging applications in medical devices, sensors, and compact cameras. The technology was developed by Prof. John Rogers at University of Illinois, Urbana-Champaign, while the medical applications were developed in collaboration with researchers at University of Pennsylvania. MC10’s technology has been covered by The Wall Street Journal, NY Times, Nature, BBC, MSNBC, etc, and has been billed by MIT’s Technology Review as “one of the 10 technologies that will change the world”.

Sera Prognostics is developing diagnostic tests that use proprietary biomarkers that are predictive of preterm birth, preeclampsia and other pregnancy complications. Sera aims to improve the health and development of children through early assessment of pregnancy complications that can guide medical interventions and lead to healthier deliveries.

SolarBridge Technologies builds and markets highly reliable solar micro-inverters to convert direct current (DC) generated by solar photovoltaic modules into alternating current (AC) that can be used by electric appliances and/or supplied back to the utility grid. The company’s products integrate directly with solar PV modules to enable AC solar modules that have several benefits including improved energy harvest and lower installation costs.